JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

First Posted Date
2008-12-25
Last Posted Date
2014-04-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
580
Registration Number
NCT00814801

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-12-09
Last Posted Date
2013-07-29
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
78
Registration Number
NCT00805142

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

First Posted Date
2008-11-24
Last Posted Date
2013-12-09
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
39
Registration Number
NCT00796003

An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-11-10
Last Posted Date
2013-06-26
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
142
Registration Number
NCT00788372

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-10-13
Last Posted Date
2015-11-03
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
311
Registration Number
NCT00771251

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Phase 1
Completed
Conditions
First Posted Date
2008-09-15
Last Posted Date
2011-05-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
35
Registration Number
NCT00752518

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Phase 2
Completed
Conditions
First Posted Date
2008-09-15
Last Posted Date
2011-05-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
119
Registration Number
NCT00752661
© Copyright 2024. All Rights Reserved by MedPath